Contents

Collaborative Ocular Melanoma Study (COMS) – MEDIUM TUMOURS


Main finding: There was no survival difference between Iodine 125 brachytherapy vs enucleation

 

  • Study name:Collaborative Ocular Melanoma Study (COMS)
  • Study type: Randomised controlled Trial
  • Condition: Choroidal melanoma

Participants: Medium choroidal melanoma
Definition
-Apical height 2.5-10mm, basal diameter 16mm or below

 

  • n=1317

 

Intervention:

 

Group 1: Brachytherapy
Group 2: Enucleation

5-year data:

 

  • No difference in survival rates between 125I brachytherapy vs enucleation at 5 years
Enucleation Brachytherapy
Death rate (5-year) 28% 27%
Survival rate (5-year) 81% 82%
Death rate with melanoma metastases (5-year) 11% 9%

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed